Company
Altoida
Enabling Early Detection for a Healthier Brain
Also known as Altoida, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- healthcare providers
- Legal name
- Altoida, Inc.
- altoida.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Record updated 17 September 2026
About
Altoida is defining a new category in neurological care with a first-of-its-kind, multi-modal platform engineered to bring clinical-grade cognitive and functional diagnostics to the front lines of healthcare. Combining augmented reality (AR), sensor fusion and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods.
Funding snapshot
- Total raised
- $14MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $14M2022-03-30
Funding rounds
- Round, 2022
- $14M2022-03-30, Company stated
Products
- Other
- Altoida NeuroMarker Platform
- Web
- Altoida NeuroMarker Platform